PAVmed Secures Financing up to $14 Million for Advancement of its Lead Products to Commercialization Nov 05, 2019 7:00am EST
PAVmed Reports Second Quarter 2019 Financial Results and Provides Business Update Sep 05, 2019 9:30am EDT
PAVmed Successfully Completes Clinical Safety Study Procedures for CarpX™ 510(k) Re-submission Aug 15, 2019 9:30am EDT
PAVmed Subsidiary Lucid Diagnostics Receives FDA 510(k) Clearance for EsoCheck™ Jun 24, 2019 10:46am EDT
PAVmed Reports First Quarter 2019 Financial Results and Provides Business Update May 21, 2019 9:30am EDT
